Cutaneous pharmacodynamics of a toll-like receptor 7 agonist, 852A, in humans

Journal of Clinical Pharmacology

Volumn 48, Issue 6, 2008, Pages 755-762

  Astry, Calvin ^a   Birmachu, Woubalem ^a   Harrison, Lester I ^a   Meng, Tze Chiang ^a  

^a 3M COMPANY   (United States)

Author keywords

852A; Cutaneous pharmacodynamics; Gene expression; Innate immunity; Toll like receptor 7

Indexed keywords

852 A; INTERFERON; N [4 [4 AMINO 2 ETHYL 1H IMIDAZO(4,5 C)QUINOLIN 1 YL]BUTYL]METHANESULFONAMIDE; SULFONAMIDE;

ADULT; APPLICATION SITE DERMATITIS; APPLICATION SITE ERYTHEMA; APPLICATION SITE IRRITATION; APPLICATION SITE PRURITUS; APPLICATION SITE REACTION; ARTICLE; BIOPSY; CCL2 GENE; CLINICAL TRIAL; CLUSTER ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; CXCL9 GENE; DEPRESSION; DRUG ABSORPTION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG TOLERABILITY; EDEMA; EXUDATE; FEMALE; GENE; GENE EXPRESSION; HEADACHE; HUMAN; HUMAN TISSUE; MALE; MUSCLE SPASM; NORMAL HUMAN; NOSE CONGESTION; OAS3 GENE; OTALGIA; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SERUM; SKIN ULCER; STOMACH DISCOMFORT; THROAT IRRITATION; XEROSTOMIA;

ADMINISTRATION, CUTANEOUS; ADULT; COHORT STUDIES; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; MALE; MIDDLE AGED; OINTMENTS; QUINOLINES; RNA, MESSENGER; SULFONAMIDES; TIME FACTORS; TOLL-LIKE RECEPTOR 7;

EID: 44049089154     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270008314466     Document Type: Article

References (19)

1. Medzhitov R., Janeway C. The toll receptor family and microbial recognition. Trends Microbiol. 2000 ; 8: 452-456.
2. Heil F., Hemmi H., Hochrein H., et al. Species-specific recognition of single-stranded RNA via Toll-like receptor 7 and 8. Science. 2004 ; 303: 1526-1531.
3. Harrison LI, Astry C., Kumar S., Yunis C. Pharmacokinetics of 852A, an imidazoquinoline toll-like receptor 7-specific agonist, following intravenous, subcutaneous, and oral administrations in humans. J Clin Pharmacol. 2007 ; 47: 962-969.
4. Dudek AZ, Yunis C., Harrison LI, et al. First in human phase I trial of a novel TLR7 agonist to activate immune responses in patients with advanced cancer. Clin Canc Res. In press.
5. Gorden KB, Gorski KS, Gibson SJ, et al. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J Immunol. 2005 ; 174: 1259-1268.
6. Gorski KS, Waller EL, Bjornton-Severson J., et al. Distinct indirect pathways govern human NK cell activation by TLR-7 and TLR-8 agonists. Int Immunol. 2006 ; 18: 1115-1126.
7. Birmachu W., Gleason RM, Bulbulian BL, et al. Transcriptional networks in plasmscytoid dendritic cells stimulated with synthetic TLR7 agonists. BMC Immunol. 2007 ; 8: 26 [Epub].
8. Stroncek DF, Basil C., Nagorsen D., et al. Delayed polarization of mononuclear phagocyte transcriptional program by type I interferon isoforms. J Transl Med. 2005 ; 3: 24.
9. de Veer MJ, Holko M., Frevel MJ, et al. Functional classification of interferon-stimulated genes identified using microarrays. J Leukoc Biol. 2001 ; 69: 912-920.
10. Khabar KS, Al-Haj L., Al-Zoghaibi F., et al. Expressed gene clusters associated with cellular sensitivity and resistance towards anti-viral and anti-proliferative actions of interferon. J Mol Biol. 2004 ; 342: 833-846.
11. Gordien E., Rosmorduc O., Peltekian C., Garreau F., Brechot C., Kremsdorf D. Inhibition of hepatitis B virus replication by the interferon-inducible MxA protein. J Virol. 2001 ; 75: 2684-2691.
12. Austin BA, James C., Silverman RH, Carr DJ Critical role for the oligoadenylate synthetase/RNase L pathway in response to IFN-beta during acute ocular herpes simplex virus type 1 infection. J Immunol. 2005 ; 175: 1100-1106.
13. Noyce RS, Collins SE, Mossman KL Identification of a novel pathway essential for the immediate-early, interferon-independent antiviral response to enveloped virions. J Virol. 2006 ; 80: 226-235.
14. Gupta AK, Cherman AM, Tyring SK Viral and nonviral uses of imiquimod: a review. J Cutan Med Surg. 2004 ; 8: 338-352.
15. Owens ML, Bridson WE, Smith SL, Myers JA, Fox TL, Wells TM Percutaneous penetration of Aldara cream, 5% during the topical treatment of genital and perianal warts. Prim Care Update Ob Gyn. 1998 ; 5: 151.
16. Harrison LI, Skinner SL, Marbury TC, et al. Pharmacokinetics and safety of imiquimod 5% cream in the treatment of actinic keratoses of the face, scalp, or hands and arms. Arch Dermatol Res. 2004 ; 296: 6-11.
17. Urosevic M., Dummer R., Conrad C., et al. Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment. J Natl Cancer Inst. 2005 ; 97: 1143-1153.
18. Torres A., Storey L., Anders M., et al. Immune-mediated changes in actinic keratosis following topical treatment with imiquimod 5% cream. J Transl Med. 2007 ; 5: 7.
19. Panelli MC, Stashower ME, Slade HB, et al. Sequential gene profiling of basal cell carcinomas treated with imiquimod in a placebo-controlled study defines the requirements for tissue rejection. Genome Biol. 2007 ; 8: R8.